One of them is Dep Radiotherapeutics which targets (locates) cancer zones in the body and delivers its anti cancer drugs to the relevant site
Telix's Molecularly Targeted Radiation platform highlights cancer cells in body....and that's it!
Telix could be an off-shoot of Starpharma. It's market cap (TLX) is currently $331 million
So the question posed....with the main technology of Telix being Molecularly Targeted Radiation and Starpharma having this and destroying the underlying cancer in situ....... as being just one of many solutions for cancer in its pipeline......surely the multi billion potential value of Starpharma is (as an understatement).....severely undervalued
SPL Price at posting:
$1.24 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)